Market Niche Expansion W.H.P.M., Inc. specializes in rapid membrane tests and recently partnered with DanceSafe to develop accessible xylazine testing strips, indicating a strategic focus on harm reduction and public health markets.
Regulatory Expertise The company is a registered GMP facility with the FDA for in vitro diagnostic devices, which can facilitate approvals and partnerships in healthcare and diagnostic sectors.
Innovation & Collaboration Recent collaborations highlight W.H.P.M.'s commitment to developing cost-effective, easy-to-use diagnostic solutions, opening opportunities for partnerships with NGOs, healthcare providers, and government agencies.
Growth Potential With reported revenues between $10 million and $25 million and a focus on rapid testing technology, there is significant potential for scaling sales within medical, harm reduction, and community health markets.
Technology Stack & Market Reach Utilizing modern web and digital tools, W.H.P.M. is positioned to enhance its online presence and reach a broader customer base, supporting sales initiatives in both private and public healthcare sectors.